LightLab Imaging v. Volcano/Axsun
This article was originally published in The Gray Sheet
Executive Summary
Damages trial is set for March 22 following a Feb. 4 jury finding that Volcano and its Axsun Technologies subsidiary misappropriated LightLab trade secrets and that Volcano intentionally interfered with a contract under which Axsun supplied to LightLab tunable lasers for use in optical coherence tomography (OCT) systems, LightLab announces Feb. 9. LightLab, which makes OCT equipment for vascular applications, filed suit in January 2009, following Axsun's acquisition by Volcano in December 2008. Volcano says it plans to appeal the jury verdict and that it "does not believe that this development will have a material impact on Volcano's OCT program or Axsun's business.
You may also be interested in...
Volcano Corp. wins ruling
Superior Court of Massachusetts rejects LightLab Imaging's claims for protection of five alleged trade secrets relating to laser technologies in a legal battle with Volcano and its wholly-owned subsidiary Axsun Technologies, Volcano announced Oct. 6. Requests from LightLab, a St. Jude Medical subsidiary, for permanent injunctions were also denied, the company noted. At the same time, a trial on remaining trade secret claims is yet to be scheduled. Volcano CEO Scott Huennekens said in a statement that the ruling "validates our position regarding these purported trade secrets" and that the company will "vigorously" defend itself against the remaining claims. A jury on Feb. 4 found that Volcano and Axsun misappropriated LightLab trade secrets, and that Volcano intentionally interfered with a contract under which Axsun supplied to LightLab tunable lasers for use in optical coherence tomography (OCT) systems. Volcano had said that it would appeal the jury verdict. LightLab filed its initial suit in January 2009 after Volcano acquired Axsun (1"The Gray Sheet" Feb. 15, 2010)
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.